Korro Bio to Participate in 2022 Jefferies Healthcare Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New York, NY, on Thursday, June 9, 2022, at 10:30 a.m. EDT.

About Korro Bio, Inc.

Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. Korro’s proprietary and modular platform, OPERATM, combines data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety, in a cost-effective drug product. As a result, Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  265.01
+5.67 (2.19%)
AAPL  302.25
+3.28 (1.10%)
AMD  447.58
+33.53 (8.10%)
BAC  51.23
+0.53 (1.05%)
GOOG  384.90
+0.00 (0.00%)
META  605.06
+2.45 (0.41%)
MSFT  421.06
+3.64 (0.87%)
NVDA  223.47
+2.86 (1.30%)
ORCL  188.16
+6.70 (3.69%)
TSLA  417.26
+13.15 (3.25%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.